Herceptin is new option in advanced HER2-positive gastric cancer, say experts
02 June 2009
Malini Guha
Roche's (Genentech) HER2-targeted breast cancer drug Herceptin (trastuzumab) was recommended by experts as a new option in HER2-positive advanced gastric cancer after it prolonged median overall survival by almost three months when added to chemotherapy in the pivotal first-line ToGA trial, the results...
Please Login to read the full article.
02 June 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- ImmunoGen to raise $84 million, adding own pipeline to Roche-licensed compounds
- US FDA to decide fate of Genentech's pertuzumab by 8 June
- GSK's Tykerb again disappoints in adjuvant breast cancer setting
- Future subcutaneous Herceptin studies could lead to patient-administration
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
